Abstract: The present invention provides an antigen binding protein comprising an antigen binding domain that binds to plasmin, wherein the antigen binding protein reduces the activity of plasmin. The invention also provides compositions comprising the antigen binding protein, and uses and method of treatment comprising the same.

Abstract: The present invention provides a method for reprogramming a human somatic cell to a cell exhibiting at least one characteristic of a trophoblast stem cell (TSC), the method comprising the following steps in order: a) increasing the protein expression of one or more factors in the somatic cell, wherein the factors are for reprogramming the somatic cell towards a pluripotent state; b) culturing the cell for a sufficient time and under conditions to allow the reprogramming of the cell towards a pluripotent state; c) contacting the cell with a culture medium suitable for sustaining trophoblast stem cells (TSC); and d) culturing the cell in the TSC medium for a sufficient time and under conditions to allow the cell to exhibit at least one characteristic of a TSC, thereby reprogramming the somatic cell to a cell exhibiting at least one characteristic of a TSC.

Abstract: The invention provides a method for detecting one or more analytes, the method comprising: providing a substrate comprising a semiconductor with a porous surface, wherein the porous surface is coated with a fluorocarbon polymeric coating; contacting the porous surface with a fluid or object so that the one or more analytes are retained on the substrate when present in the fluid or on the object; and analysing the substrate by mass spectrometry to detect the one or more analytes if present on the substrate.

Abstract: The present invention relates to compounds and their uses, in particular, compounds in the form of prodrugs that promote transport of a pharmaceutical agent to the lymphatic system and subsequently enhance release of the parent drug.

Abstract: A method for maintaining a cell in vitro that comprises the steps of: providing a cell of interest in cell culture, determining differential breadth of histone 3 trimethylated at lysine 4 (H3K4me3) modified regions and a differential broadness score for each protein-coding gene in said cell, determining a network score for each protein-coding gene in said cell based on the differential broadness score and interactions between the protein products of each protein-coding gene over at least one network, and determining a cell identity score for each protein-coding gene in said cell based on a combination of the differential broadness score and network scores. The cell identity scores are used to prioritise protein-coding genes thereby identifying cell identity genes for said cell, which encode factors associated with cell identity. The cell of interest is cultured in the presence of said factors, thereby maintaining the cell identity of the cell of interest.

Abstract: A transistor comprises a planar layer of a topological material located between a gate electrode and a dielectric layer. The topological material exhibits a topological phase transition between a trivial state and a non-trivial state at a critical electric field strength on application of an electric field in a direction perpendicular to the planar layer. The topological material exhibits a change in bandgap, in the presence of the electric field, having a Rashba spin-dependent bandgap contribution that is at least three times as large as a non-spin-dependent bandgap contribution.

Abstract: The present invention provides methods of treating metabolic diseases including obesity, insulin resistance and type 2 diabetes with inhibitors of COX-2 or VEGFR and lipid prodrugs of COX-2 inhibitors, in particular celecoxib lipid prodrugs, that promote transport of the pharmaceutical agent to the lymphatic system and which enhance release of the parent agent.

Abstract: The present invention relates to compounds and their uses, in particular, compounds in the form of prodrugs that promote transport of a pharmaceutical agent to the lymphatic system and subsequently enhance release of the parent drug.

Abstract: The present invention provides lymphatic system-directing lipid prodrugs, pharmaceutical compositions thereof, methods of producing such prodrugs and compositions, and methods of improving the bioavailability or other properties of a therapeutic agent that comprises part of the lipid prodrug. The present invention also provides methods of treating a disease, disorder, or condition such as those disclosed herein, comprising administering to a patient in need thereof a disclosed lipid prodrug or a pharmaceutical composition thereof.

Abstract: The invention provides a method of continuous electrochemical dinitrogen reduction to produce ammonia, the method comprising: supplying dinitrogen to an electrochemical cell comprising an electrolyte in contact with at least a cathode; introducing protons to the electrolyte by anodic oxidation of a hydrogen-containing species; and cathodically reducing the dinitrogen in the presence of a metal selected from lithium, magnesium, calcium, strontium, barium, zinc, aluminium and vanadium to produce ammonia, wherein the electrolyte comprises a cationic proton carrier capable of reversible deprotonation to form a neutral proton acceptor, wherein the neutral proton acceptor is an ylide.

Abstract: An isolated or purified AON for modifying pre-mRNA splicing in the Receptor for Advanced Glycation End-products (RAGE) to modulate splicing of the RAGE gene transcript or part thereof is provided.

Abstract: Disclosed herein is a method for co-pyrolysis of a polyolefin and a rubber containing material comprising: operating at least a pyrolysis stage of a pyrolysis reactor at an operating temperature at or above the temperature at which pyrolysis of both the polyolefin and the rubber containing material commences and up to about 600° C. under a substantially inert atmosphere; feeding a mixture comprising the polyolefin and the rubber containing material into the pyrolysis reactor; co-pyrolysing the mixture in the pyrolysis reactor to produce a pyrolysis gas comprising volatile pyrolysis products of the polyolefin and the rubber, wherein the volatile pyrolysis product of the olefin comprises at least a short chain olefin and the volatile product of the rubber comprises at least a diene; and facilitating a gas phase reaction between the short chain olefin and the diene to produce a volatile gas comprising single-ring aromatic hydrocarbons.

Abstract: The present invention relates to compounds and their uses, in particular, compounds in the form of prodrugs that promote transport of a pharmaceutical agent to the lymphatic system and subsequently enhance release of the parent drug.

Abstract: The present invention relates to polypeptides, particularly fusion protein variants comprising interleukin-37 (IL-37) and related therapeutics and compositions thereof. More particularly, the invention relates to fusion proteins comprising a mutant IL-37 polypeptide and an Fc region of an antibody. The biophysical stability such as thermal stability of said fusion proteins can be improved compared to a reference IL-37 construct, such as a wild-type IL-37 polypeptide or a mutant variant of an IL-37 polypeptide. It also relates to the fusion polypeptide variants and compositions for use in treating inflammatory diseases or conditions. In addition, the present invention relates to nucleic acid molecules encoding such fusion proteins, and vectors and host cells comprising such nucleic acid molecules.

Abstract: The present invention relates to stem cells derived from a multi-layered cellular structure or blastocyst structure, compositions comprising the same, and methods for obtaining the same.

Abstract: The present invention relates to compounds and their uses, in particular, compounds in the form of prodrugs that promote transport of a pharmaceutical agent to the lymphatic system and subsequently enhance release of the parent drug.

Abstract: The present disclosure generally relates to a method for reducing the toxicity of inhaled polymyxins as a therapeutic agent comprising the step of co-administration of an aminoglycoside; a method for improving the aerosolization of an aminoglycoside comprising the step of combination formulation with a polymyxin; and a process for manufacturing a dry powder composition comprising a polymyxin and aminoglycoside. Pharmaceutical compositions and methods of treatment for lung infections are within the scope of this invention.

Abstract: The present invention relates to compounds and their uses, in particular, compounds in the form of prodrugs that promote transport of a pharmaceutical agent to the lymphatic system and subsequently enhance release of the parent drug.

Abstract: The present disclosure is directed to human protease activated receptor 4 (PAR4) binding proteins (e.g. antibodies). In particular, anti-PAR4 binding proteins which are antagonists of human PAR4, as well as methods and uses thereof.

Abstract: The present invention relates to compounds and their uses, in particular, compounds in the form of prodrugs that promote transport of a pharmaceutical agent to the lymphatic system and subsequently enhance release of the parent drug.